DT120
Major Depressive Disorder (MDD)
Key Facts
About Definium Therapeutics
Definium Therapeutics, formerly MindMed, is a science-led biotech company dedicated to developing next-generation psychedelic therapeutics for serious psychiatric conditions. Its strategy centers on pharmaceutical optimization of classical compounds like LSD and MDMA to create proprietary, scalable treatments. The company's lead asset, DT120, is in multiple Phase 3 trials for Generalized Anxiety Disorder and Major Depressive Disorder, positioning it as a frontrunner in the emerging psychedelic medicine sector. Definium aims to redefine treatment success by targeting the root causes of disorders, moving beyond symptom management to enable functional recovery.
View full company profileAbout Definium Therapeutics
Definium Therapeutics, formerly MindMed, is a science-led biotech company dedicated to developing next-generation psychedelic therapeutics for serious psychiatric conditions. Its strategy centers on pharmaceutical optimization of classical compounds like LSD and MDMA to create proprietary, scalable treatments. The company's lead asset, DT120, is in multiple Phase 3 trials for Generalized Anxiety Disorder and Major Depressive Disorder, positioning it as a frontrunner in the emerging psychedelic medicine sector. Definium aims to redefine treatment success by targeting the root causes of disorders, moving beyond symptom management to enable functional recovery.
View full company profileAbout Definium Therapeutics
Definium Therapeutics, formerly MindMed, is a science-led biotech company dedicated to developing next-generation psychedelic therapeutics for serious psychiatric conditions. Its strategy centers on pharmaceutical optimization of classical compounds like LSD and MDMA to create proprietary, scalable treatments. The company's lead asset, DT120, is in multiple Phase 3 trials for Generalized Anxiety Disorder and Major Depressive Disorder, positioning it as a frontrunner in the emerging psychedelic medicine sector. Definium aims to redefine treatment success by targeting the root causes of disorders, moving beyond symptom management to enable functional recovery.
View full company profileAbout Definium Therapeutics
Definium Therapeutics, formerly MindMed, is a science-led biotech company dedicated to developing next-generation psychedelic therapeutics for serious psychiatric conditions. Its strategy centers on pharmaceutical optimization of classical compounds like LSD and MDMA to create proprietary, scalable treatments. The company's lead asset, DT120, is in multiple Phase 3 trials for Generalized Anxiety Disorder and Major Depressive Disorder, positioning it as a frontrunner in the emerging psychedelic medicine sector. Definium aims to redefine treatment success by targeting the root causes of disorders, moving beyond symptom management to enable functional recovery.
View full company profileAbout Definium Therapeutics
Definium Therapeutics, formerly MindMed, is a science-led biotech company dedicated to developing next-generation psychedelic therapeutics for serious psychiatric conditions. Its strategy centers on pharmaceutical optimization of classical compounds like LSD and MDMA to create proprietary, scalable treatments. The company's lead asset, DT120, is in multiple Phase 3 trials for Generalized Anxiety Disorder and Major Depressive Disorder, positioning it as a frontrunner in the emerging psychedelic medicine sector. Definium aims to redefine treatment success by targeting the root causes of disorders, moving beyond symptom management to enable functional recovery.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Preclinical |
| Deep TMS (H1 Coil) | BrainsWay | FDA Cleared |
| EXXUA™ (gepirone ER) | Aytu BioPharma | Commercial |
| INV-202 (Oral & LAI) | Indivior | Preclinical |
| Gepirone ER | Fabre-Kramer Pharmaceuticals | NDA Submitted |
| Exablate Neuro | Insightec | Clinical Trial |
| BrightKaire Platform for Depression | NeuroKaire | Pre-clinical |
| Tyemvers (CKDB-501) | Healis Therapeutics | Pre-clinical |
| VENTURA-7 | New Hope Clinical Research | Phase 2/3 |
| DT-101 | Draig Therapeutics | Phase 2 |
| Major Depressive Disorder Program | Actipulse Neuroscience | Phase 3 |
| Flow tDCS Headset & App | Flow Neuroscience | Approved |